This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
The civil lawsuit, alleging anti-competitive practices by Portland firm LegitScript, may move to Oregon venue.
A Pfizer win in a lawsuit against the federal government could cost taxpayers billions of dollars and erase an important control on pharma marketing after decades of regulatory erosion and soaring drug prices, say health policy analysts.
The bill would tie U.S. drug prices to a median price in 11 countries where prescriptions are much cheaper.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
But they face drug industry opposition as they consider bills to make generic drugs more available, limit out-of-pocket insulin costs and set price limits on expensive drugs.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
The state released its latest drug transparency data, which shows that Humira, used for rheumatoid arthritis, racked up $81 million in sales over the past year.
The state's Legislature has overwhelmingly approved a measure that would direct the state’s top health agency to partner with one or more drug companies by January to make or distribute a broad range of generic or biosimilar drugs.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
A legislative proposal for importing wholesale prescription drugs from Canada has died -- for the second time.
House Bill 4147 was effectively killed by House health care leaders who did not put it on the committee agenda.
During the 2020 State of the Union address, President Donald Trump zeroed in on prescription drug prices, arguing that his administration is “taking on the big pharmaceutical companies.”
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
Oregon lawmakers are considering changes to the state’s drug transparency law that would prevent pharmaceutical manufacturers from exploiting a potential loophole to avoid reporting price hikes and give state regulators more authority to expect timely information from drug companies.
House Democrats are poised to pass sweeping legislation to lower drug prices using strategies President Donald Trump has endorsed. A Trump aide urged the Republican-controlled Senate to vote on a different package curbing drug prices that was drafted by a senior Republican.
